中文产业新闻精选评分69Chinese source
EyePoint 长效眼科新药 DURAVYU 湿性 AMD 三期 LUGANO 试验失败 股价大跌 67%
长效眼科新药 III 期失败，股价大跌 67%
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
长效眼科新药 III 期失败，股价大跌 67%
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.